To include your compound in the COVID-19 Resource Center, submit it here.

Onxeo's Livatag misses in Phase III for HCC

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) reported top-line data from the Phase III ReLive trial in 397 patients with

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE